NOT-HL-22-023: Notice of Change in Application Due Date for RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)"

Notice of Change in Application Due Date for RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)"

Notice Number:

NOT-HL-22-023

Key Dates

Release Date:

May 16, 2022

Related Announcements

RFA-HL-21-013 - Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform applicants of changes to the Application Due Dates and and Expiration Date for RFA-HL-21-013 "Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required)". Specifically, this Notices changes only the remaining due date and the related expiration date:

Part 1. Overview Information

Key Dates

Current Key Dates
Application Due Date(s): July 24, 2020, March 19, 2021, January 10, 2022, June 1, 2022.
Expiration Date: June 2, 2022

Modified Key Dates (changes shown in bold italics):
Application Due Date(s): July 24, 2020, March 19, 2021, January 10, 2022, July 15, 2022.
Expiration Date: July 16, 2022

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Antonello Punturieri, MD, PhD
Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0233
Email: [email protected]